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Abstract
Background: Febrile neutropenia carries a high risk of sepsis complications, and the identification of biomarkers 
capable to identify high risk patients is a great challenge. Angiopoietins (Ang -) are cytokines involved in the control 
microvascular permeability. It is accepted that Ang-1 expression maintains endothelial barrier integrity, and that Ang-2 
acts as an antagonizing cytokine with barrier-disrupting functions in inflammatory situations. Ang-2 levels have been 
recently correlated with sepsis mortality in intensive care units.
Methods: We prospectively evaluated concentrations of Ang-1 and Ang-2 at different time-points during febrile 
neutropenia, and explored the diagnostic accuracy of these mediators as potential predictors of poor outcome in this 
clinical setting before the development of sepsis complications.
Results: Patients that evolved with septic shock (n = 10) presented higher levels of Ang-2 measured 48 hours after 
fever onset, and of the Ang-2/Ang-1 ratio at the time of fever onset compared to patients with non-complicated sepsis 
(n = 31). These levels correlated with sepsis severity scores.
Conclusions: Our data suggest that imbalances in the concentrations of Ang-1 and Ang-2 are independent and early 
markers of the risk of developing septic shock and of sepsis mortality in febrile neutropenia, and larger studies are 
warranted to validate their clinical usefulness. Therapeutic strategies that manipulate this Ang-2/Ang-1 imbalance can 
potentially offer new and promising treatments for sepsis in febrile neutropenia.
Background
Despite improvements in supportive care, sepsis remains
the most common cause of death in intensive care units,
with mortality rates of 30% to 50 [1,2]. Recently, therapies
targeting elements from the inflammatory and coagula-
tion cascades yielded disappointing results in clinical tri-
als [3-5], possibly due to redundancy within the
inflammatory pathways activated during sepsis. Endothe-
lial barrier disruption plays a key role in the pathogenesis
of sepsis and septic shock, making it an attractive target
for studies aimed to identify new therapeutic targets for
sepsis [6]. Recently, the participation of VEGF, a vascular
growth factor with potent microvascular permeability
functions, in the pathogenesis of septic shock was dem-
onstrated [7]. Another important regulator of endothelial
barrier function are the angiopoietins (Ang) -1 and -2,
and the tyrosine kinase receptor Tie2 expressed in
endothelial cells. Binding of Ang-1 to Tie2 maintains the
quiescent resting state of the endothelium and reduces
vascular permeability in response to inflammatory stim-
uli. In contrast, Ang-2 inhibits biding of Ang-1 to Tie2,
resulting in vessel destabilization [8-10]. Circulating lev-
els of Ang-1 and Ang-2 have been recently evaluated in
patients with sepsis, and levels of Ang-2 have been corre-
lated with sepsis severity in children [11] and adults [12-
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15], when evaluated in patients admitted to intensive care
units with established signs and symptoms of sepsis.
Febrile neutropenia (FN) in patients with hematologic
malignancies is characterized by increased susceptibility
to sepsis complications, and a higher risk of septic shock,
with mortality ranging from 2-21% [16]. Most patients
with FN are well at the time of fever onset. However, ways
to predict the development of fulminant sepsis and septic
shock is a great challenge in the care of these patients
[17,18]. Here we evaluated the time-course of Ang-1 and
Ang-2 expression in FN patients early in the course of
sepsis and explored the diagnostic accuracy of Ang-1 and
Ang-2 levels as potential predictors of poor outcome in
this clinical setting.
Methods
Patient's eligibility criteria
Recruitment of patients took place at the Bone Marrow
Transplantation Unit of University of Campinas between
March 2008 and March 2009. Patients were included if
they fulfilled the following criteria: (1) diagnosis of hema-
tological malignancies, and (2) admission as inpatients
for intensive chemotherapy (induction for acute leukemia
or high-dose sequential therapy for lymphomas) or
hematopoietic stem-cell transplantation (HSCT).
Patients were invited to participate before the initiation
of any chemotherapy regimen. Fever (T ≥ 38.0°C) at
admission was the only exclusion criteria. The study was
performed in accordance with the Declaration of Helsinki
and approved by the local Ethics Committee. Informed
written consent was obtained from all patients prior to
collection of samples. Only patients that presented fever
during neutropenia (defined as a neutrophil count <500
μl) were included in the second phase of the study.
Descriptive data consisting of demographics, diagnosis,
clinical data, and disease severity scores were obtained
from the medical records. Twenty healthy individuals vol-
unteered to determine a normal reference range for Ang-
1 and Ang-2 levels (10 males, 10 females; median age 40 -
range 24 to 53).
Sepsis definitions and risk stratification scores
An infectious etiology was assumed for all patients with
post chemotherapy neutropenia with new onset fever, in
accordance with FN management protocols. Blood and
urine cultures were immediately obtained and broad-
spectrum antibiotics were initiated [19]. Sepsis, in this
population, was defined by the presence of two or more
of the following: (1) temperature > 38.0°C, (2) heart
rate>90 beats/min, (3) respiratory rate > 20 breaths/min
or PaCO2 < 32 mmHg, and a microbiologically proven or
clinically evident source of infection. Septic shock was
present in patients in which sepsis was complicated with
hypoperfusion or hypotension (systolic arterial pressure
<90 mmHg or a reduction in systolic blood pressure of
>40 mmHg from baseline), despite adequate volume
resuscitation. Patients were subdivided into two outcome
groups: sepsis (non-complicated) and septic shock.
Severity of illness was assessed by calculating the Sequen-
tial Organ Failure Assessment (SOFA) score [20] daily
after the development of fever, and by calculation of the
Multinational Association for Supportive Care In Cancer
(MASCC) score at the time of fever [21,22].
Laboratory measurements
Venous blood was drawn at enrollment (baseline), within
12 hours after first episode of neutropenic fever, and 48
hours thereafter. Samples were immediately centrifuged
at 3000 rpm (4°C, 20 mins) and plasma and serum was
stored at -80°C until analysis. Samples were processed by
the same investigator. Serum levels of Ang-1 and Ang-2
were measured in duplicate using a commercial enzyme-
linked immunosorbent assay (ELISA) kit (Quantikine,
R&D Systems, Minneapolis, MN, USA) according to the
manufacturer's instructions. Interassay coefficient of
variations were 2.95% for Ang-1 and 6.87% for Ang-2
samples with concentrations within the range observed in
our study. Von Willebrand Factor (VWF) levels were
measured in duplicate in citrate plasma samples using a
rabbit anti-human VWF peroxidase conjugate (Dako
Netherlands BV, Heverlee, Belgium).
Statistical Analysis
Patients were divided in two outcome subgroups accord-
ing to the presence of absence of septic shock at any time
point before the resolution of FN. Differences in continu-
ous variables between patients from each subgroup, and
between patients and healthy controls were analyzed
using the Mann-Whitney rank sum test. Categorical vari-
ables were compared using the Fisher's exact test. Data
are expressed as median and range unless otherwise
stated. Correlation (Spearman's rank correlation) and lin-
ear regression analysis were performed between sepsis
severity scores and angiopoietin concentrations. Receiver
operator characteristics (ROC) procedures were used to
identify optimal cut-off values of angiopoietin concentra-
tions to differentiate patients with non-complicated sep-
sis and patients with septic shock. A second analysis was
performed to explore the effect of angiopoietin concen-
trations on 30-day mortality, calculated from the day of
fever onset. Survival curves were estimated using the
Kaplan-Meier method. Parameters independently associ-
ated with survival were identified by univariate and mul-
tivariate Cox proportional hazards models. Variables
found to be statistically significant at a 10% level in the
univariate analyses were included in the multivariate
model. Different models were established, and variable
selection was performed by different forward and back-Alves et al. BMC Infectious Diseases 2010, 10:143
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ward procedures, with comparable results. A p value less
than or equal to 0.05 was considered statistically signifi-
cant. All statistical analysis were performed with the
SPSS package (SPSS Inc., Chicago, IL, USA) and the
GraphPad Prism Software (GraphPad Prism Software
Inc. San Diego, California, USA).
Results
Patients Characteristics
A total of 60 patients fulfilled the primary criteria for
study entry, of which 41 patients experienced neutro-
penic fever and completed the study (Figure 1). Charac-
teristics of these patients are shown in Table 1. In 10/41
patients (24%), septic shock was present before the reso-
lution of neutropenia, and all of them required mechani-
cal ventilation. The median time to the development of
septic shock was 4.1 days (range 1 - 7 days) after the first
episode of neutropenic fever, and in only one patient, sep-
tic shock onset occurred in the first 48 hours after the
first episode of neutropenic fever. Eight patients died
within the first 30 days after the onset of fever, reaching a
30-day mortality of 13.3%. All deaths were attributed to
complications of septic shock. The only clinical signifi-
cant difference between patients with non-complicated
sepsis and septic shock were: (1) age, (2) presence of
bloodstream infection, (3) sepsis severity score SOFA cal-
culated 48 hours after fever onset, and (4) MASCC at the
time of neutropenic fever. An anatomic site of infection
was established in 10 (24%) patients. Compared to
healthy individuals, patients presented lower baseline lev-
els of Ang-1, and similar baseline levels of Ang-2 (Table
2).
Time-course of Ang-1 serum levels in hematological 
patients with FN
At baseline, no difference in Ang-1 levels could be
observed between patients with non-complicated sepsis
and with septic shock (Table 2). No statistical significant
difference could be detected between Ang-1 levels in
patients with non-complicated sepsis (185.46 pg/ml,
range 9.30-3206.40 pg/ml) or with septic shock (82.34 pg/
ml, range 9.30-571.05 pg/ml; Mann-Whitney test, p =
0.29) at the time of fever onset. After 48 hours, Ang-1 lev-
els remained similar in patients with non-complicated
sepsis (129.27 pg/ml, range 9.30-8485.10 pg/ml) and in
patients with septic shock (105.10 pg/ml, range 9.30-
3510.60 pg/ml; Mann-Whitney test, p = 0.90) (Figure 2).
Time-course of Ang-2 serum levels in hematological 
patients with FN
At baseline, no statistically significant difference could be
observed in levels of Ang-2 between patients from the
two groups (Table 2). Furthermore, Ang-2 levels were
similar at the time of neutropenic fever between patients
with non-complicated sepsis (105.55 pg/ml, range 19.40-
1653.50 pg/ml) and septic shock (152.39 pg/ml, range
19.97-644.27 pg/ml). However, 48 hours after neutro-
penic fever a striking difference could be observed
between patients with and without septic shock, with
markedly increased Ang-2 concentrations in patients
with septic shock (840.77 pg/ml, range 30.67-2085.30 pg/
ml) compared to patients with non-complicated sepsis
(91.10 pg/ml, range 19,40-785,24 pg/ml; Mann-Whitney
test: p = 0.002) (Figure 2). We estimated the diagnostic
accuracy of Ang-2 levels measured 48 hours after fever
onset. Ang-2 48 hours after fever onset yielded an area
under the ROC curve of 0.84 (95%CI = 0.65-1.0; P =
0.004). In our population, an optimal cut-off value of
Ang-2>233 pg/ml predicted the development of septic
shock with a sensitivity of 75% (95%CI = 34.9%-96.8%)
and a specificity of 92.6%(95%CI = 75.7%-99.1%).
The Ang-2/Ang-1 ratio is increased in FN patients that 
evolve to septic shock
The Ang-2/Ang-1 ratio was calculated in an effort to
detect relevant changes in the relative concentration of
these two antagonistic mediators of microvascular per-
meability. At the time of neutropenic fever, the Ang-2/
Ang-1 ratio was much higher in patients with septic
shock (6.80, range 0.03-17.20) compared to patients with
non-complicated sepsis (0.80, range 0.01-16.8; Mann-
Whitney test: p = 0.05). After 48 hours, the Ang-2/Ang-1
ratio was higher in patients that developed septic shock
(10.58, range 0.10-101.70) compared to patients with
non-complicated sepsis (0.40, range 0.01-18.70), but sta-
tistical significance was not reached (Mann-Whitney test:
P = 0.06) (Figure 2). Estimation of the diagnostic accuracy
of the Ang-2/Ang-1 ratio at fever onset yielded an area
under the ROC curve of 0.71 (95%CI = 0.50-0.93; P =
0.05). In our population, a median Ang-2/Ang-1 ratio of
1.17, which was the optimal cut-off value identified by the
ROC procedure, predicted the development of septic
shock with a sensitivity of 77.8% (95%CI = 40.0%-97.2%)
and a specificity of 60% (95% CI = 40.6%-77.3%).
Serum Ang-1 and Ang-2 levels correlate with severity of 
illness score (SOFA)
We next evaluated whether serum Ang-1 and Ang-2 lev-
els correlated with the SOFA score. We utilized the SOFA
score calculated 48 hours after fever because it segregates
e a c h  o u t c o m e  g r o u p  b e t t e r  t h a n  S O F A  a t  t h e  t i m e  o f
fever onset (Table 1). Significant correlations were
observed between SOFA and the following parameters:
Ang-2 48 h after fever (Rs = 0.40; P = 0.02), Ang-2/Ang-1
ratio at fever onset (Rs = 0.51; P = 0.001) and Ang-2/Ang-
1 ratio 48 h after fever (Rs = 0.35; P = 0.04) (Figure 3).Alves et al. BMC Infectious Diseases 2010, 10:143
http://www.biomedcentral.com/1471-2334/10/143
Page 4 of 10
Table 1: Patient characteristics
Characteristics Sepsis ¥
(n = 31)
Septic shock
(n = 10)
P
Sex (male:female) 13:18 7:3 0.16 **
Age (median, range) 37 (16-55) 55 (24-62) P < 0.01 *
Diagnosis
Acute leukemias 17 4
Other € 14 6
Disease status 0.12 **
Complete remission 13 (42%) 1 (10%)
Active disease 18 (58%) 9 (90%)
Treatment 0.48 **
Intensive CTx/autologous HSCT 17 6
Allogeneic HSCT 14 4
Neutrophils/μl - Fever (median, range) 60 (0 - 290) 50 (20 - 470) 0.40 *
Days of neutropenia (median, range) 12 (4 - 22) 14 (7 - 30) 0.36 *
Platelets × 103/μl - fever (median, range) 25 (6 - 169) 38 (12 - 90) 0.16 *
Days with fever (median, range) 4 (1 - 12) 5 (1 - 12) 0.65 *
SOFA score - fever onset (median, range) 3 (0 - 7) 4 (2 - 8 ) 0.31 *
SOFA score - 48 hours (median, range) 4 (2 - 7) 7 (4 - 16) P = 0.01 *
MASCC score (median, range) 21 (16 - 23) 18 (11 - 24) P = 0.03 *
Agent isolation in bloodstream (yes:no) £ 4:27 8:2 P < 0.001 **
Von Willebrand Factor U/ml - fever 
(median, range)
205.12(88.94 -341.95) 262.72 (208.19-430.09) 0.11 *
¥ Non-complicated sepsis; *Mann-Whitney test; **Fisher's exact test; €: Lymphoma (n = 8); Multiple Myeloma (n = 5); Myeloproliferative 
diseases (n = 5); Paroxysmal Nocturnal Hemoglobinuria (n = 2); HSCT: Hematopoietic stem cell transplantation; CTx: chemotherapy. £: Gram 
negative: n = 7; Gram positive: 7; Fungi: n = 2 (4 patients with mixed flora infections).Alves et al. BMC Infectious Diseases 2010, 10:143
http://www.biomedcentral.com/1471-2334/10/143
Page 5 of 10
Ang-2/Ang-1 ratio at fever onset and 30-day mortality in 
patients with FN
To determine the relationship of angiopoietin levels with
30-day mortality, we initially performed univariate Cox
proportional hazards analysis, in which the following
variables were found to be statistically significant: age,
duration of neutropenia, SOFA, MASCC, Ang-2 (48
hours after fever) and Ang-2/Ang-1 ratio (both at fever
onset and 48 hours thereafter). We then performed mul-
tivariate Cox regression analysis incorporating these vari-
ables, and the only variable that remained statistically
significant in the multivariate setting was the Ang-2/Ang-
1 ratio, measured at fever onset (Hazard ratio 1.20 -
95%CI 1.02-1.41; P < 0.01). Figure 4 illustrates the
Kaplan-Meier curve of 30-day survival stratified to less
versus greater than the median values of Ang-2/Ang-1
ratio at fever onset. Logrank confirmed statistical signifi-
cance. The 30-day mortality of patients with Ang-2/Ang-
1 ratio below 1.17 was 5.5% compared to 31.6% for
patients with greater ratios.
Discussion
Post chemotherapy FN in patients with hematological
malignancies is a condition that carries a high risk of sep-
sis complications with mortality rates as high as 21% [16],
usually preceded by septic shock. Patients with FN are a
heterogeneous group in terms of risks of complications
and mortality, and the identification of parameters capa-
ble to accurately identify high risk patients is one of the
great challenges in their care. Clinical scores such as the
MASCC [21], and laboratory parameters such as C-reac-
tive protein, IL-6, IL-8 and procalcitonin have been
recently proved to be useful tools for this purpose [23].
However, it is generally acknowledged that these parame-
ters are more useful to identify patients at low risk for
complications, leaving room for refinements in the risk
stratification of FN patients. Ideally, one such marker
should be easily detected in samples obtained before the
development of severe sepsis, and should not be influ-
enced by cytopenias or by the inflammatory milieu asso-
ciated with disease status. Elements that are directly
involved in the pathogenesis of sepsis complications are
thus more attractive candidates than non-specific ele-
ments of the inflammatory cascade.
Angiopoietins are a family of vascular growth factors
with critical roles in embryonic and postnatal angiogene-
sis. Ang-1 and Ang-2 both act on the Tie2 tyrosine kinase
receptor found primarily on endothelial cells, but appear
to play antagonist roles [10]. Apparently, Ang-1 promotes
vessel stabilization whereas Ang-2 is involved in the
destabilization of newly formed vessels. These processes
of disassemble and reassemble of the endothelial lining of
primitive blood vessels is important because it allows the
incorporation of new endothelial cells to growing
endothelial tubes, leading eventually to the formation of
functional and mature blood vessels [24]. A role of angio-
poietins in the pathogenesis of septic shock is supported
by multiple lines of evidence. First, increased levels of
Ang-2 levels have been demonstrated in adult and pediat-
ric patients with sepsis in intensive care units (ICU) and
these levels correlated with sepsis severity [11,12,14,25].
Second, serum from patients with sepsis has been shown
to disrupt endothelial architecture, an effect that corre-
lates with Ang-2 levels, is reversed by Ang-1 and is mim-
icked by recombinant Ang-2 [14]. Finally, Ang-2 levels
have been shown to correlate with pulmonary permeabil-
ity edema and occurrence of acute respiratory distress
syndrome in mechanically ventilated patients [26]. More
recently, Kumpers et al, studying a population of 43 med-
ical ICU patients demonstrated that Ang-2 levels at the
time of ICU admission was a strong predictor of mortal-
ity [12]. Ang-1 levels were also evaluated in some of these
studies, but so far studies have failed to a relationship
between Ang-1 and sepsis outcomes.
In our prospective study we explored the time-course
of Ang-1 and Ang-2 in a population of patients with high
Table 2: Baseline levels of Ang-1 and Ang-2 in the study population
Healthy individuals (N = 20) Patients (N = 41) P*
Ang-1 (pg/ml) 8799.70 (4795.10-14644.00) 3746.90 (76.43-51780.00) <0.0001
Ang-2 (pg/ml) 41.01 (19.40-246.09) 48.37 (18.81-2892.10) 0.88
Sepsis € (n = 31) Septic shock (n = 10)
Ang-1 (pg/ml) 4156.60 (100.33-51780.00) 3224.00 (76.43-6117.50) 0.30
Ang-2 (pg/ml) 55.22 (19.40-2892.10) 26.04 (18.10-218.60) 0.24
* Mann-Whitney test; € Non-complicated sepsisAlves et al. BMC Infectious Diseases 2010, 10:143
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risk of sepsis complications before the development of
severe sepsis. As far as we are aware, the significance of
Ang-1 and Ang-2 levels has not been studied in patients
with FN. An additional contribution of our study is that
we prospectively evaluated the significance of Ang-1 and
Ang-2 levels at an earlier time-point in the development
of sepsis (which developed in a median time of 4.1 days
after fever onset), as opposed to studies that evaluated
patients at the ICU. This difference is evidenced by the
median SOFA score of our patients (4 range 1-8) com-
pared to higher median SOFA scores (16 range 1-22)
from other key studies [12]. Last, Ang-1 and Ang-2 levels
were serially evaluated at three time points, thus offering
a view of the time-course of Ang-1 and Ang-2 release in
the early hours of sepsis.
For this study we only included patients with hemato-
logical malignancies and FN after intensive chemother-
apy that were treated as inpatients from day one of
chemotherapy until the resolution of neutropenia. By
doing so, we intended to obtain a representative sample
of patients with high risk of sepsis complications. F ur -
thermore, the fact that all patients were treated as inpa-
tients allowed us to standardize important variables that
could affect the validity of our results such as the time
between fever onset and sample collection. So as to limit
as much as possible the influence of different diagnosis
and chemotherapy regimens on our results, Ang-1 and
Ang-2 levels were also collected immediately before the
initiation of chemotherapy, allowing differences between
outcome groups to be compared not only as absolute val-
ues, but also as fold-increase from baseline levels, which
did not alter our results (data not shown). In fact, neither
Ang-1 nor Ang-2 levels were significantly different before
the initiation of chemotherapy between patients with
non-complicated sepsis and septic shock, supporting the
uniformity of our group of patients as far as the two study
variables were concerned.
The main finding of our study is that the relative con-
centration of Ang-1 and Ang-2 are different in subgroups
of patients with FN that evolve to non-complicated sepsis
compared to patients that develop septic shock, and that
evaluation of these two proteins within the first 48 hours
after neutropenic fever, before the development of any
signs and symptoms of septic shock, is a promising tool
to discriminate high risk patients with FN. In accordance
with previous studies, Ang-2 levels were significantly
higher in patients with septic shock compared to patients
with non-complicated sepsis. This difference was not
present at the time of fever onset, rose sharply and
became evident after 48 hours, when levels in the poorer
outcome group were 8 times higher than in the good out-
come group. Importantly, Ang-2 baseline levels were sim-
ilar. As in previous studies, we were not able to detect any
significant difference of Ang-1 levels between study
groups. However, when the relative concentrations of
these two antagonistic cytokines were evaluated, we did
observe a relative deficiency of Ang-1 compared to Ang-2
levels in patients that developed septic shock, that was
evident early at the time of fever onset. It has been known
for more than a decade that Ang-1 can protect adult vas-
culature against VEGF-induced plasma leakage [10].
Ang-1 has also been shown to protect mice from endo-
toxic shock [27]. In this respect, it is tempting to specu-
late that the imbalance between Ang-1 and Ang-2 levels
present already at the time of fever onset is associated
with a poorer outcome of sepsis in FN, and possibly in
other patients with sepsis. This hypothesis is well illus-
trated in our work by the divergent trend of Ang-2/Ang-1
ratio observed in each outcome subgroup of patients.
Early in the course of sepsis, patients that evolved to sep-
tic shock presented a 7-fold increase in the Ang-2/Ang-1
ratio, whereas patients with non-complicated sepsis pre-
sented a 0.8 decrease when compared to baseline (pre-
chemotherapy) ratios. After 48 hours, this divergent
trend persisted, with patients that evolved to septic shock
presenting a 10-fold increase, and patients with non-
complicated sepsis with a 0.4-fold decrease. We also eval-
uated VWF antigen levels, which is increased in patients
with sepsis [28], and is an indicator of endothelial dys-
Figure 1 Flowchart of the study.Alves et al. BMC Infectious Diseases 2010, 10:143
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Figure 2 Serum angiopoietin levels in patients with febrile neutropenia stratified by outcome group. Box plots representing serial concentra-
tions of angiopoietins in patients with febrile neutropenia that presented non-complicated sepsis (n = 31) or septic shock (n = 10). Ang-1 at the time 
of fever onset (a) and after 48 hours (b). Ang-2 at the time of fever onset (c) and after 48 hours (d). Ang-2/Ang-1 ratio at the time of fever onset (e) and 
after 48 hours (f). Horizontal bars indicate median values. Mann-Whitney test.Alves et al. BMC Infectious Diseases 2010, 10:143
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function and stimulation [29]. In contrast to Ang-2, no
difference could be observed between both patient
groups at any time-point (table 1). We also demonstrated
a significant, though weak correlation of Ang-2 concen-
trations 48 hours after fever onset and of Ang-2/Ang-1
ratio (both at fever onset and after 48 hours) with the
SOFA score of sepsis severity. Based on these results, we
estimated diagnostic accuracy of Ang-2 concentrations
48 hours after fever and of Ang-2/Ang-1 ratio at fever
onset. Despite wide confidence intervals, area under the
ROC curves suggest that both biomarkers should be fur-
ther investigated as promising tools to discriminate high-
risk FN patients in studies with larger sample sizes. The
relationship between angiopoietin concentrations and
30-day mortality was also evaluated. Using a multivariate
Cox model, we demonstrate that the Ang-2/Ang-1 ratio
at the time of fever onset can be an independent predic-
tor of sepsis survival in our population, an observation
that will have to be validated in larger studies.
Recently, the time course of Ang-1 and Ang-2 release
was evaluated in a model of human endotoxemia [13],
which showed that Ang-2 release is initiated 2.5 hours
after LPS challenge, and observed no significant varia-
tions in levels of Ang-1. Ang-2 is a Weibel-Palade body-
stored molecule that is rapidly released upon endothelial
stimulation. In contrast, Ang-1 is believed to exert its ves-
sel-sealing effect by low-level constitutive activation of
the Tie2 receptor, in a model in which constitutive Ang-
1/Tie2 interactions control endothelial barrier integrity as
a default pathway, and Ang-2 acts as a dynamically regu-
lated antagonizing cytokine [30]. Our results showing
that patients that evolve to septic shock present an initial
relative deficiency of Ang-1 associated with a sharp
increase in Ang-2 levels in the first 48 hours of sepsis sup-
ports that similar events can be involved in the pathogen-
esis of septic shock in FN.
There are certain limitations of our study that need to
be acknowledged to avoid overinterpretation of its con-
clusions. Research about new diagnostic tools follow a
sequence of phases along which the questions answered
by each phase progress from the demonstration tha t a
Figure 3 Correlation of angiopoietin levels with the SOFA sepsis 
severity score. Scatter plots showing linear regression analysis be-
tween Sequential Organ Failure Assessment (SOFA) scores and (a) 
Ang-2 concentrations measured 48 h after fever onset, (b) Ang-2/Ang-
1 ratio measured at fever onset (b) and 48 hours thereafter (c).
Figure 4 Survival of patients with febrile neutropenia according 
to Ang-2/Ang-1 ratio at the time of fever onset. Kaplan-Meier curve 
(less versus greater than median; * Logrank test.Alves et al. BMC Infectious Diseases 2010, 10:143
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biomarker behaves differently in diseased and normal
individuals (phase I) to the ultimate demonstration of
improved clinical outcomes after its incorporation (phase
IV) [31]. Ours is a phase II study in which the perfor-
mance of a new diagnostic assay was tested in patients
with a defined condition (febrile neutropenia) and poten-
tial different outcomes, but in which several confounding
variables were controlled. Phase II studies tell us whether
the test shows diagnostic promise under ideal conditions.
Therefore, our study design does not allow us to univer-
salize our conclusions to clinical settings where the
impact of treatment related and other variables might
reject our conclusions. For the formal validation of the
assay and its incorporation intro clinical practice, a larger
sample size (ideally from distinct centers) under less con-
trolled conditions should be used. The relatively low
number of deaths used for the multivariate analysis also
deserves to be discussed. Our study design required a
very specific population of patients, with stringent inclu-
sion criteria to control confounding variables, so that a
further increase in sample size was not feasible. On the
other hand, it has been demonstrated that relaxing the
rule of 10 events per variable in Cox models is possible
without unacceptable increases in confounding bias [32].
With this in mind, we believe that as long as the above-
mentioned limits of our study are acknowledged, the
association of 30-day mortality with Ang-2/Ang-1 ratio is
an important information to the literature.
Conclusions
In summary, our data suggest that imbalances in the con-
centrations of Ang-1 and Ang-2 present already at the
time of the first fever peak is an independent marker of
the risk of developing septic shock and of 30-day mortal-
ity in FN. Further studies are warranted to validate this
new biomarker as clinically relevant tool in the daily care
of these patients. In addition, therapeutic strategies
designed to manipulate the Ang-2/Ang-1 imbalance can
offer a new and promising paradigm for the treatment of
sepsis and septic shock in patients with FN.
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